Mumbai : Denmark-based Novo Nordisk launched ‘Novoeight’ in the country for treatment and prevention of bleeding in people with haemophilia A.
“We have launched Novoeight in India for use in the treatment and prevention of bleeding in people with haemophilia A (congenital factor VIII deficiency) across all age groups. It can also be used to prevent excessive bleeding in people with haemophilia A undergoing surgery,” a company statement issued here said.
“Turoctocog alfa represents a new treatment alternative for people with haemophilia A and is one of the first important outcomes of the haemophilia research strategy we embarked upon about a decade ago. The approval of ‘Novoeight’ marks an important step in offering a new alternative for people with haemophilia A,” Novo Nordisk Corporate Vice President Business Area Gulf, India and Egypt, Mads Bo Larsen said.
Haemophilia is a chronic, inherited bleeding disorder that primarily affects males. People with haemophilia A are either missing or have a malfunctioning factor VIII protein, which is essential for proper blood clotting.